Endometrial Neoplasms
Conditions
Keywords
diet, time restricted eating (TRE), Native Hawaiian or other Pacific Islander, endometrial cancer risk, randomized crossover trial
Brief summary
The long-term goal of this study is to determine the efficacy of time restricted eating (TRE) for improving metabolic health and preventing endometrial cancer. The primary objective of the protocol is to conduct a 14-week two-arm randomized crossover trial of a dietary intervention to evaluate the feasibility, fidelity and preliminary acceptability of a TRE intervention among Native Hawaiian/Pacific Islander women at risk for developing endometrial cancer, and to provide proof of principle that TRE can improve metabolic health in this population.
Detailed description
Enrollment: The study includes two phases. Phase 1 includes focus groups among 30 Native Hawaiian/Pacific Islander women at risk of endometrial cancer. Focus groups will determine sociocultural influences on (i) dietary behavior including meal timing; (ii) dietary preferences; (iii) proposed meal plans and intervention design; (iv) perceptions of weight loss and body image. In the second study phase, the study team will recruit 10 Pacific Islander women to participate in a 14-week randomized dietary crossover study. Each woman will participate in both intervention arms and act as her own control. Focus Group: To accomplish all aspects of Aim 1 of this study, the study team will recruit 30 Pacific Islander women at risk for endometrial cancer to conduct virtual focus groups. These focus groups will take place via private videoconference, like Zoom, and a language translator will be provided, as necessary. The focus groups will be attended by a Native Hawaiian/Pacific Islander Community Expert. Questions will be designed to understand sociocultural influences on dietary behavior (questions on social eating, meal timing, and dietary preferences, soliciting feedback on study intervention delivery design, and perceptions of weight loss and body image). An icebreaker will be conducted prior to formal questioning. Sessions will be audio-recorded on the videoconference and an additional device, transcribed verbatim, and checked for accuracy. Two additional team members will be present as note takers. Our Community Expert will be present to help facilitate the session. Questions will be provided at the beginning of the session to ensure cultural sensitivity. Dietary Intervention: The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule, 4-week washout period, and a 4-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (8 to 10-hour feeding and 14 to 16-hour fasting periods). A follow-up questionnaire will be mailed 6-months post- intervention. For the control schedule, women will receive frozen lunch and dinner meals and a standardized breakfast and snacks menu. All meals and the breakfast/snack menu will be designed to be culturally competent with feedback from the focus groups, and meal plans will be individualized to meet weight maintenance energy requirements. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. They will be asked to maintain their regular sleep and physical activity schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day. All meals (control and TRE) will be provided by the Metabolic Kitchen located at the University of Utah. Visit 1: During the baseline visit, a coordinator will obtain consent from the participant, and they will be asked to compete questionnaires asking about clinical and demographic factors, chronotype, and physical activity, and various anthropometric measurements will be taken. Following the baseline visit, participants will undergo a 2-week run-in period. During this time, the goal is to record women's usual times of eating episodes and appetite while following their habitual diet. Visit 2: Women will provide fasting blood and stool samples, and anthropometric measurements will be taken. Following visit 2, participants will undergo the control or TRE schedule for 4 weeks. Visit 3: After 4 weeks, participants will undergo visit 3 and will be asked to provide fasting blood and stool samples, and anthropometric measures will be taken. Following visit 3, participants will undergo a 4-week washout period, where women are able to return to their usual lifestyle. Visit 4: Visit 4 will occur after the 4-week washout period, and will include a telephone consultation to discuss the next study phase and schedule meal provision. For the following 4-weeks, participants will then undergo the opposite feeding schedule (either control or TRE). Visit 5: During the final visit, women will provide fasting blood and stool samples, and anthropometric measures will be taken. During the run-in period, the TRE phase and the control phase, participants will record timing of eating episodes using the MyCircadian Clock phone app, complete 3 x 24-hour diet recalls, a single physical activity recall, and 7-days of sleep and physical activity will be objectively measured using an Actiwatch device. Hunger and satiety will be evaluated at random through the MyCircadian Clock phone app. A study exit interview will be conducted via Zoom conference call to debrief on the intervention and obtain detailed information on acceptability of the protocol. Approximately 6-months after the end of the intervention period, women will complete a mailed follow-up questionnaire.
Interventions
Women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. They will be asked to maintain their regular sleep and physical activity schedule. Fasting period will ramp up during the first week (e.g., Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the feeding period at the same time each day. They will be allowed to consume water and 1-2 servings of very low-calorie drinks and foods (e.g., herbal tea, diet drinks, mints, gum containing \< 4 kcal/serving) to increase compliance. All meals (control and TRE) will be provided by the Metabolic Kitchen developed in collaboration with the department of Nutrition and Integrative Physiology.
Women will receive frozen lunch/dinner meals and a standardized breakfast and snacks menu. All meals and the breakfast/snack menu will be designed to be culturally competent. The meal plans will be individualized to meet weight maintenance energy requirements.
Sponsors
Study design
Eligibility
Inclusion criteria
All Aims: * Native Hawaiian/Pacific Islander females aged 18 years or older * Overweight or obese (BMI\>25kg/m2) OR have a history of non-insulin dependent diabetes OR have a history of complex atypical endometrial hyperplasia * Have a working cell phone that can download an App * Able to use cell phone during day (e.g. at work) * Not a night shift worker Applicable Only to Aims 2 \& 3: * Able to attend study visits at the Huntsman Cancer Institute Center for HOPE
Exclusion criteria
All Aims: * Unable to provide informed consent Applicable Only to Aims 2 \& 3: * Necessity of a special diet that precludes adjustment of meal timing and/or macronutrient content * Have a history of insulin dependent diabetes * Have a history of hysterectomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants Referred That Were Consented and Enrolled | up to 1 day after screening | The feasibility of the Time-Restricted Eating (TRE) intervention will be measured by calculating the proportion (%) of women who were consented and enrolled in the study out of all the participants who screened for the trial. |
| Attrition | From the baseline of the randomized portion of the study to Visit 5, up to 19 weeks | To assess the feasibility of the TRE intervention. This outcome measure will report the number of participants who withdrew throughout the course of the interventional component of the study. |
| Protocol Items Completed | From the baseline of the randomized portion of the study to Visit 5, up to 19 weeks | This outcome measure will report the count of participants who completed each study assessment per protocol. Participants who were randomized and withdrew from the study are included as missed assessments. After the TRE Schedule (Visit 3 or 5), waist circumference, weight, blood pressure, blood, and stool were collected. After the Control Schedule (Visit 3 or 5), waist circumference, weight, blood pressure, blood, and stool were collected. This outcome measure will report the count of participants who completed each assessment |
| Percentage of TRE-Adherent Days | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | This outcome measure will report the mean percentage of TRE-adherent days. TRE adherence is achieved when participants fast for 14-18 hours per day during the TRE phase, as measured by a mealtime log using the MyCircadianClock phone app. |
| Meals Delivered On Schedule | From the baseline of the randomized portion of the study to Visit 5, up to 19 weeks | Count of participants whose pre-made control diet meals were delivered on schedule. Participants were provided with pre-made, frozen lunch and dinner meals 7 days a week during both 4-week diet phases. |
| Study Visit Completion | From the baseline of the randomized portion of the study to Visit 5, up to 19 weeks | To assess feasibility of the study, the percentage of in-person study visits completed out of 5 study visits for each participant was calculated. This outcome measure will report the mean percentage of completed study visits. This outcome measure was assessed throughout the course of the study during both the TRE and Control Schedules; it is not possible to regroup participants to report Arms/Groups "per intervention". |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood Pressure Measured With Electronic Blood Pressure Monitor | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Blood pressure was measured using an electronic blood pressure monitor after the TRE phase and after the control diet phase. |
| Waist Circumference | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Waist circumference was measured by trained study staff using a tape measure and standardized protocols. Waist circumference was measured after the TRE Schedule and after the Control Schedule. |
| Body Mass Index (BMI) Assessed Via Stadiometer and Calibrated Scales | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Participants' height and weight was measured by trained study staff using a stadiometer and calibrated weighing scales. Measures were done in triplicate (duplicate if measures did not agree). Height and weight were used to calculate body mass index in kilograms divided by height in meters-squared. BMI was measured after the TRE Schedule and after the Control Schedule. |
| Fasting Blood Glucose Level | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Fasting glucose was measured at Associated Regional and University Pathologists (ARUP) Laboratories. Fasting blood samples were taken from participants by a trained phlebotomist using standard protocols after the TRE Schedule and after the Control Schedule. |
| Fasting Blood C-peptide Level | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | C-peptide was measured at ARUP Laboratories. Fasting blood samples were taken by a trained phlebotomist using standardized protocols after the TRE Schedule and after the Control Schedule. |
| Fasting Blood Triglyceride Level | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Blood triglyceride level was measured at ARUP Laboratories. Fasting blood samples were taken by a trained phlebotomist using standardized protocols after the TRE Schedule and after the Control Schedule. |
| Fasting Blood High-density Lipoprotein(HDL)-Cholesterol Level | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Blood HDL-cholesterol level was measured at ARUP Laboratories. Fasting blood samples were taken by a trained phlebotomist using standardized protocols after the TRE Schedule and after the Control Schedule. |
| Fasting Blood High Sensitivity C-reactive Protein | From the baseline of the randomized portion of the study to Visit 3 and Visit 5, up to 19 weeks | Blood C-peptide level was measured at ARUP Laboratories. Fasting blood samples were taken by a trained phlebotomist using standardized protocols after the TRE Schedule and after the Control Schedule. |
Countries
United States
Contacts
University of Utah
Participant flow
Pre-assignment details
25 participants who participated in the focus groups did not continue to the randomized portion of the study.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants |
| Age, Continuous | 32.63 years STANDARD_DEVIATION 8.84 |
| Body Mass Index | 39.97 Kg/m^2 STANDARD_DEVIATION 8.53 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 36 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment United States | 6 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 0 Participants |
| Waist (cm) | 119.30 cm STANDARD_DEVIATION 19.4 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 14 |
| other Total, other adverse events | 0 / 14 | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 14 |